Repeat infections with RSV are believed to be common ... from a targeted pathogen in a proprietary parainfluenza virus 5 vector. Clinical data have shown that administration of our intranasal ...

Blue Lake Biotechnology, Inc., a clinical-stage intranasal vaccine company developing parainfluenza virus 5 (PIV5)-vectored vaccines that harness the full breadth of the immune system to protect ...

Respiratory syncytial virus (RSV) is a highly contagious and ... from a targeted pathogen in a proprietary parainfluenza virus 5 vector. Clinical data have shown that administration of our ...

Five years ago, on March 11, the World Health Organization declared COVID-19 a global pandemic. The vaccines “underwent the most intensive safety analysis in U.S. history." ...

Respiratory syncytial virus (RSV) is a highly contagious and common respiratory ... by expressing a protein from a targeted pathogen in a proprietary parainfluenza virus 5 vector. Clinical data have ...

Arrow Therapeutics focused exclusively on novel antiviral drug discovery and development, including several different approaches towards Hepatitis C and Respiratory Syncytial Virus (RSV).

Among older adults in Spain, hospitalization rates from respiratory syncytial virus (RSV) infection increases progressively ...

Among older adults in Spain, hospitalization rates from respiratory syncytial virus (RSV) infection increases progressively with age and is more likely among people with other health issues and who ...

The man’s case didn’t give rise to any widespread variant, but it gave Gupta, with his HIV evolution background, the idea ...

Respiratory syncytial virus (RSV) is the most important cause of infantile bronchiolitis and pneumonia. It is ubiquitous, with most children acquiring their primary infection within the first year ...

Dengue virus, a WHO grade 3 emergency, infected over 10 million individuals in 2024. With no population-effective prophylaxis or direct treatment, there is an urgent need for immediate vector control ...

Already competing to bring the first vaccine against respiratory syncytial virus (RSV) to market, Pfizer and GSK are also fighting a patent infringement battle in the courts. Earlier this month ...